Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| EPI40463 | |||
| WEUKSTV1113 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
There is a lack of toxicology data on one bupropion metabolite, and limited literature examining bupropion use and cancer risk. This study evaluates the association between bupropion exposure and the development of cancer of the prostate, breast, lung, colon/rectum, urinary bladder, and uterus by comparing the risk of cancer in bupropion users with other antidepressant users. Because there is no evidence that bupropion is associated with any particular cancer, we have chosen the six most common cancers diagnosed in the United States to optimize statistical power/precision for cancer-site specific comparisons. Two US population-based data resources with automated claims, pharmacy, and tumor registry data are included in this study. Using a nested case-control design, this study will compare the incidence of cancer in patients exposed to bupropion with the incidence in patients exposed to other antidepressants.
Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymised and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| New users of antidepressants Jan. 1, 1996 to Dec. 31, 2006 | All new users of antidepressants January 1, 1996 through December 31, 2006. Individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Regular bupropion use | Drug | Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | The following are the cancers under investigation: colorectal, lung, bladder, uterus, breast, and prostate. Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | January 1, 1996 - December 31, 2006 |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, colorectal cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Colorectal cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. |
Not provided
Inclusion Criteria:
-
Exclusion Criteria:
Not provided
Not provided
Not provided
New users of antidepressants January 1, 1996 through December 31, 2006, regardless of indication for use (depression, smoking cessation, other) in Henry Ford Health System and Kaiser Permanente Health Plan of Northern California. The study population is limited to individuals 18 years of age or older with medical and pharmacy benefits and at least 6 months of health plan enrollment before the first antidepressant prescription. Patients with a history of any cancer (cancer diagnosis recorded in the tumor registries anytime before the first antidepressant prescription recorded during the study period) are excluded. Cases and controls will be selected from this cohort of antidepressant-exposed study subjects.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| GSK Clinical Trials | GlaxoSmithKline | Study Director |
Not provided
Not provided
Patients were not recruited for nor enrolled in this study. This study is a retrospective observational study. Data from medical records or insurance claims databases are anonymized and used to develop a patient cohort. All diagnoses and treatment are recorded in the course of routine medical practice.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | New Antidepressant Exposure in Colorectal Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Cases |
| FG001 | New Antidepressant Exposure in Colorectal Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Controls |
| FG002 | New Antidepressant Exposure in Lung Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Cases |
| FG003 | New Antidepressant Exposure in Lung Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Controls |
| FG004 | New Antidepressant Exposure in Bladder Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Cases |
| FG005 | New Antidepressant Exposure in Bladder Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Controls |
| FG006 | Antidepressant Exposure in Uterine Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Cases |
| FG007 | New Antidepressant Exposure in Uterine Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Controls |
| FG008 | New Antidepressant Exposure in Breast Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Cases |
| FG009 | New Antidepressant Exposure in Breast Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Controls |
| FG010 | New Antidepressant Exposure in Prostate Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Cases |
| FG011 | New Antidepressant Exposure in Prostate Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Controls |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | New Antidepressant Exposure in Colorectal Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Cases |
| BG001 | New Antidepressant Exposure in Colorectal Cancer: Controls |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Customized | Number |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Diagnosed With Any of the Cancers Under Investigation Who Were Regularly Exposed to the Indicated Antidepressant | The following are the cancers under investigation: colorectal, lung, bladder, uterus, breast, and prostate. Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | Participants diagnosed with colorectal, lung, bladder, uterus, breast, or prostate cancer who were new antidepressant users | Posted | Number | participants | January 1, 1996 - December 31, 2006 |
|
Not provided
This is a retrospective study of pre-existing data; thus, no assessments for Serious or Non-serious Adverse Events were performed.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | New Antidepressant Exposure in Colorectal Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Cases |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| GSK Response Center | GlaxoSmithKline | 866-435-7343 |
Not provided
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D009369 | Neoplasms |
| ID | Term |
|---|---|
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D017367 | Selective Serotonin Reuptake Inhibitors |
| D000929 | Antidepressive Agents, Tricyclic |
| ID | Term |
|---|---|
| D014179 | Neurotransmitter Uptake Inhibitors |
| D049990 | Membrane Transport Modulators |
| D045504 | Molecular Mechanisms of Pharmacological Action |
| D020228 | Pharmacologic Actions |
Not provided
Not provided
Not provided
Not provided
Not provided
| Regular SSRI (Selective serotonin reuptake inhibitors) use | Drug | Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. |
|
| Regular TCA (Tricyclic antidepressants) use | Drug | Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. |
|
| Regular use of any other antidepressant | Drug | Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An "other antidepressant" would be any antidepressant other than bupropion, a SSRI or a TCA. |
|
| January 1, 1996 - December 31, 2006 |
| Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, lung cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Lung cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | January 1, 1996 - December 31, 2006 |
| Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, bladder cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Bladder cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | January 1, 1996 - December 31, 2006 |
| Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, uterine cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Uterine cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | January 1, 1996 - December 31, 2006 |
| Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, breast cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Breast cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | January 1, 1996 - December 31, 2006 |
| Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, prostate cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Prostate cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | January 1, 1996 - December 31, 2006 |
New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Controls |
| BG002 | New Antidepressant Exposure in Lung Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Cases |
| BG003 | New Antidepressant Exposure in Lung Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Controls |
| BG004 | New Antidepressant Exposure in Bladder Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Cases |
| BG005 | New Antidepressant Exposure in Bladder Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Controls |
| BG006 | New Antidepressant Exposure in Uterine Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Cases |
| BG007 | New Antidepressant Exposure in Uterine Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Controls |
| BG008 | New Antidepressant Exposure in Breast Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Cases |
| BG009 | New Antidepressant Exposure in Breast Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Controls |
| BG010 | New Antidepressant Exposure in Prostate Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Cases |
| BG011 | New Antidepressant Exposure in Prostate Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Controls |
| BG012 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Number of participants diagnosed with the indicated conditions and using the indicated therapies | A value of "0" indicates that no data are available for that particular treatment arm. Smoking status data were not collected for breast cancer and prostate cancer cases and controls, as it is not a necessary variable for analysis. NSAIDS, non-steroidal anti-inflammatory drugs. | Number | participants |
|
Regular Bupropion use was defined as 4 times per week for 3 months at least 12 months before index date
| OG001 | All Non-bupropion Antidepressants, Regular Use | Regular antidepressant use of non-bupropion was defined as use of non-bupropion antidepressant for 4 times per week for 3 months at least 12 months before index date |
| OG002 | Tricyclic Antidepressants (TCA), Regular Use | Regular TCA use was defined as use of TCA for 4 times per week for 3 months at least 12 months before index date |
| OG003 | Selective Serotonin Reuptake Inhibitors (SSRI), Regular Use | Regular SSRI use was defined as use of SSRI antidepressant for 4 times per week for 3 months at least 12 months before index date |
| OG004 | Other Antidepressants, Regular Use | Regular "other" antidepressant use was defined as use other antidepressant aside from Bupropion, TCA, and SSRI for 4 times per week for 3 months at least 12 months before index date |
|
|
|
| Secondary | Number of Participants Diagnosed With Colorectal Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, colorectal cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Colorectal cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | Participants diagnosed with colorectal cancer who were new antidepressant users. | Posted | Number | participants | January 1, 1996 - December 31, 2006 |
|
|
|
|
| Secondary | Number of Participants Diagnosed With Lung Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, lung cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Lung cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | Participants diagnosed with lung cancer who were new antidepressant users. | Posted | Number | participants | January 1, 1996 - December 31, 2006 |
|
|
|
|
| Secondary | Number of Participants Diagnosed With Bladder Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, bladder cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Bladder cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | Participants diagnosed with bladder cancer who were new antidepressant users. | Posted | Number | participants | January 1, 1996 - December 31, 2006 |
|
|
|
|
| Secondary | Number of Participants Diagnosed With Uterine Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, uterine cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Uterine cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | Participants diagnosed with uterine cancer who were new antidepressant users. | Posted | Number | participants | January 1, 1996 - December 31, 2006 |
|
|
|
|
| Secondary | Number of Participants Diagnosed With Breast Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, breast cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Breast cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | Participants diagnosed with breast cancer who were new antidepressant users. | Posted | Number | participants | January 1, 1996 - December 31, 2006 |
|
|
|
|
| Secondary | Number of Participants Diagnosed With Prostate Cancer Who Were Regularly Exposed to the Indicated Antidepressant | In this outcome, prostate cancer is under investigation: Cancer case were nested within a cohort of new antidepressant users. New antidepressant users were defined as no previous antidepressant prescription in the previous 6 months. Prostate cancer cases were identified and matched with controls from the same new-user cohort. Cal year, calendar year; dx, diagnosis; IBD, Inflammatory Bowel Disease; OC, oral contraceptive; HRT/ERT, hormone replacement therapy/estrogen replacement therapy; NSAID, non-steroidal anti-inflammatory drug. | Participants diagnosed with prostate cancer who were new antidepressant users. | Posted | Number | participants | January 1, 1996 - December 31, 2006 |
|
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | New Antidepressant Exposure in Colorectal Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Colorectal Cancer: Controls | 0 | 0 | 0 | 0 |
| EG002 | New Antidepressant Exposure in Lung Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Cases | 0 | 0 | 0 | 0 |
| EG003 | New Antidepressant Exposure in Lung Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Lung Cancer: Controls | 0 | 0 | 0 | 0 |
| EG004 | New Antidepressant Exposure in Bladder Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Cases | 0 | 0 | 0 | 0 |
| EG005 | New Antidepressant Exposure in Bladder Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Bladder Cancer: Controls | 0 | 0 | 0 | 0 |
| EG006 | New Antidepressant Exposure in Uterine Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Cases | 0 | 0 | 0 | 0 |
| EG007 | New Antidepressant Exposure in Uterine Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Uterine Cancer: Controls | 0 | 0 | 0 | 0 |
| EG008 | New Antidepressant Exposure in Breast Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Cases | 0 | 0 | 0 | 0 |
| EG009 | New Antidepressant Exposure in Breast Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Breast Cancer: Controls | 0 | 0 | 0 | 0 |
| EG010 | New Antidepressant Exposure in Prostate Cancer: Cases | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Cases | 0 | 0 | 0 | 0 |
| EG011 | New Antidepressant Exposure in Prostate Cancer: Controls | New Antidepressant Exposure (defined as no antidepressant exposure within previous 6 months) in Prostate Cancer: Controls | 0 | 0 | 0 | 0 |
GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
| D020164 | Chemical Actions and Uses |
| D018377 | Neurotransmitter Agents |
| D018490 | Serotonin Agents |
| D045505 | Physiological Effects of Drugs |
| D000928 | Antidepressive Agents |
| D011619 | Psychotropic Drugs |
| D002491 | Central Nervous System Agents |
| D045506 | Therapeutic Uses |
| Controls |
|
| 1.2 |
| 95 |
| 0.8 |
| 2.0 |
Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. |
| Superiority or Other |
| Crude Odds Ratio | 1.2 | 95 | 0.8 | 2.0 | Superiority or Other |
| Adjusted Odds Ratio | 1.1 | 95 | 0.7 | 1.9 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 1.3 | 95 | 0.8 | 2.1 | Superiority or Other |
| Adjusted Odds Ratio | 1.1 | 95 | 0.7 | 1.9 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 2.2 | 95 | 1.2 | 3.9 | Superiority or Other |
| Adjusted Odds Ratio | 2.0 | 95 | 1.1 | 3.6 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Controls |
|
| 3.0 |
| 95 |
| 2.0 |
| 4.4 |
Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. |
| Superiority or Other |
| Crude Odds Ratio | 4.0 | 95 | 2.8 | 5.8 | Superiority or Other |
| Adjusted Odds Ratio | 2.9 | 95 | 1.9 | 4.5 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 4.4 | 95 | 3.1 | 6.3 | Superiority or Other |
| Adjusted Odds Ratio | 3.0 | 95 | 1.9 | 4.5 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 4.5 | 95 | 2.8 | 7.2 | Superiority or Other |
| Adjusted Odds Ratio | 3.5 | 95 | 2.1 | 5.9 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Controls |
|
| 2.1 |
| 95 |
| 1.3 |
| 3.4 |
Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. |
| Superiority or Other |
| Crude Odds Ratio | 2.3 | 95 | 1.4 | 3.6 | Superiority or Other |
| Adjusted Odds Ratio | 1.8 | 95 | 1.1 | 3.0 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 2.3 | 95 | 1.5 | 3.7 | Superiority or Other |
| Adjusted Odds Ratio | 1.8 | 95 | 1.1 | 3.0 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 2.6 | 95 | 1.5 | 4.5 | Superiority or Other |
| Adjusted Odds Ratio | 2.2 | 95 | 1.3 | 3.9 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Controls |
|
| 0.7 |
| 95 |
| 0.4 |
| 1.2 |
Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. |
| Superiority or Other |
| Crude Odds Ratio | 0.6 | 95 | 0.4 | 1.1 | Superiority or Other |
| Adjusted Odds Ratio | 0.6 | 95 | 0.3 | 1.0 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 0.8 | 95 | 0.5 | 1.4 | Superiority or Other |
| Adjusted Odds Ratio | 0.8 | 95 | 0.4 | 1.4 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 1.1 | 95 | 0.6 | 2.0 | Superiority or Other |
| Adjusted Odds Ratio | 1.0 | 95 | 0.6 | 1.9 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status†, previous depression dx, previous IBD‡ diagnosis, OC§ use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Controls |
|
| 0.9 |
| 95 |
| 0.8 |
| 1.1 |
Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. |
| Superiority or Other |
| Crude Odds Ratio | 1.0 | 95 | 0.9 | 1.2 | Superiority or Other |
| Adjusted Odds Ratio | 1.0 | 95 | 0.8 | 1.1 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 1.0 | 95 | 0.8 | 1.1 | Superiority or Other |
| Adjusted Odds Ratio | 0.9 | 95 | 0.8 | 1.1 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 1.1 | 95 | 0.9 | 1.3 | Superiority or Other |
| Adjusted Odds Ratio | 1.1 | 95 | 0.9 | 1.2 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Controls |
|
| 1.2 |
| 95 |
| 1.0 |
| 1.3 |
Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. |
| Superiority or Other |
| Crude Odds Ratio | 1.2 | 95 | 1.0 | 1.4 | Superiority or Other |
| Adjusted Odds Ratio | 1.2 | 95 | 1.0 | 1.4 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 1.1 | 95 | 0.9 | 1.2 | Superiority or Other |
| Adjusted Odds Ratio | 1.1 | 95 | 0.9 | 1.3 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |
| Crude Odds Ratio | 1.0 | 95 | 0.9 | 1.2 | Superiority or Other |
| Adjusted Odds Ratio | 1.0 | 95 | 0.8 | 1.2 | Adjusted for age, sex, cal year, study site, tumor characteristics, multiple antidepressants exposure, smoking, hysterectomy status, previous depression dx, previous IBD diagnosis, OC use, HRT/ERT use, and NSAID use. | Superiority or Other |